Biotechs testing for COVID-19 in Asia-Pacific benefit from new fast-track review processes

24th April 2020 (Last Updated June 22nd, 2020 12:38)

Sponsored by Novotech Sponsored by Visit Company
Biotechs testing for COVID-19 in Asia-Pacific benefit from new fast-track review processes
On 16 March, Peru implemented strict lockdown measures to keep its population at home and limit the number of people congregating in the same areas and spreading the virus. Credit: Shutterstock

Many countries in the Asia-Pacific region are now fast-tracking their COVID-19 clients’ clinical trials with expedited review processes for treatment and vaccine candidates.

The South Korean Ministry of Food and Drug Safety (MFDS) has announced its “GO-expedite” program whereby it is expediting the review process for COVID-19 treatment and vaccine trials with specific timelines. 

A biotech’s COVID-19 trial was just approved in less than nine days in South Korea.

Other countries also fast-tracking COVID-19 trial reviews include:

  • India: review/approval in 10 working days
  • Thailand: review/approval in 15 working days
  • Malaysia: review/approval in 20 working days

Because of this move by the region’s governing bodies, as well as the general speed and quality available in the region, it has seen a large swell in demand from biotechnology sponsors for studies in the Asia-Pacific. This expedited review process will further support the race for COVID-19 treatments, as biotech sponsors are pleased to see such a rapid response in the region to support vital research.

More than 350 clinical trials are currently taking place or are planned across the APAC region, according to GlobalData, a provider of Healthcare data analytics.

A majority of sites interested in new studies

Enormous progress has been made across the Asia-Pacific region allowing clinical trials to continue. Many clinical trial sites continue to be interested in new studies and the review and approval of non-COVID-19 clinical trials are continuing across Asia-Pacific.

Many sites across Australia, South Korea, Hong Kong and Taiwan for example appear to adapt to the situation well. A majority of sites are still able to deliver the clinical trial for biotech clients.

South Korea in particular has handled the epidemic with one of the world’s most efficient and fast responses to reduce the virus spread. South Korea is known to host some of the largest hospitals in the world which are also highly active in biotech clinical research.

For more in-depth research into why the APAC region is so well-placed to deliver COVID-19 research, check out pharmaceutical research company Novotech’s white paper about the topic below.

Free Whitepaper

The benefits of running clinical trials in Asia-Pacific for biotech companies

According to a recent report by Frost & Sullivan, the CRO market is expected to grow to $71.7 billion by 2024 – and a full 15% of that is allocated to the APAC region. The reasons for this are numerous, including:

  • locations outside of the traditional markets are needed
  • increasingly middle class and middle aged population is excellent for trials
  • smoother regulatory requirements, while still maintaining high quality
  • government financial incentives for FIH trials

In this white paper, Singapore-based Novotech shows with hard data and experience why running your clinical trial through a CRO in Asia-Pacific will save you money, get rid of communications issues by having a trial supervisor on the ground and get to market faster with the same quality. Download it now to read the full benefits and experience of biotechs who have run successful trials in the region.

Enter your details here to receive your free whitepaper.